Background
Vertex Pharmaceuticals developed Casgevy, a gene therapy for sickle cell disease and transfusion-dependent beta-thalassemia. Because the chemotherapy used during treatment may impair fertility, Vertex created a program offering Casgevy patients up to $70,000 for fertility services. Vertex sought an HHS advisory opinion before extending the program to patients receiving federally funded healthcare.
More than a year after Vertex submitted its request, HHS concluded that the program would implicate both the Anti-Kickback Statute and the Beneficiary Inducement Statute. HHS also found insufficient evidence that the program qualified for the Beneficiary Inducement Statute’s exception for remuneration that promotes access to care and poses a low risk of harm. Vertex challenged the advisory opinion and HHS regulations that delayed and tolled the statutory period for issuing advisory opinions. The district court granted summary judgment to HHS on all claims.
The Court’s Holding
The D.C. Circuit affirmed the judgment concerning the Anti-Kickback Statute. It held that “induce” carries its ordinary meaning of influencing or prevailing upon a person and that “remuneration” broadly includes valuable compensation, not merely corrupt payments. Because Vertex’s program offered up to $70,000 in fertility support to encourage patients who might otherwise decline Casgevy to choose the treatment, HHS correctly determined that the program would run afoul of the statute.
The court reversed on the Beneficiary Inducement Statute because HHS failed to meaningfully address Vertex’s evidence that the program promoted access to care and posed a low risk of harm. Its unexplained assertion that it lacked sufficient data was arbitrary and capricious. The court also held that Vertex had standing to challenge HHS’s timing regulations and set aside provisions allowing HHS to start the 60-day period only upon formal acceptance or to toll it while seeking information or outside advice. Congress required HHS to issue an advisory opinion within 60 days after receiving a request. The court affirmed in part, reversed in part, and remanded for further proceedings consistent with its opinion.
Key Takeaways
- The Anti-Kickback Statute reaches valuable payments intended to influence the purchase of federally reimbursable healthcare, even when the transaction is not inherently corrupt.
- HHS must provide a reasoned explanation addressing material evidence when deciding whether a program qualifies for the Beneficiary Inducement Statute’s access-to-care exception.
- HHS may not delay the start of, or toll, the statutory 60-day deadline for issuing advisory opinions.
Why It Matters
The decision confirms a broad interpretation of the Anti-Kickback Statute that can reach patient-assistance programs designed to mitigate treatment-related costs. Beneficial purposes and a low perceived risk of fraud do not, by themselves, place remuneration outside the statute.
At the same time, the ruling requires HHS to substantively evaluate evidence supporting exceptions to civil beneficiary-inducement liability and enforces a firm 60-day deadline for advisory opinions. Healthcare companies seeking guidance on patient-support programs therefore gain stronger procedural protections, even as the substantive anti-kickback restrictions remain broad.